Key facts
- Ahammune’s last known valuation is $24.4M.
- It has raised $7.2M; the latest was Later Stage VC ($5.0M) in Sep 2024.
- Notable investors include Indian Angel Network, Venture Center, Survam Partners, Legacy Assets, Ajith Kamath — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Ahammune
- ·The full record, as it builds
Funding rounds
No funding rounds for Ahammune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ahammune
Developer of novel drugs designed to treat the early stages of Vitiligo. The company's drugs aim to arrest new immune triggers that destroy melanocytes by effector T cells by targeting the activation step of immune cells, and these molecules prevent further killing and spread of depigmentation, enabling medical practitioners to identify cellular pathways and restore them to their homeostatic state using small molecules to maintain skin health.
- Sector
- Healthcare
- HQ
- Pune, India
- Founded
- 2016
- Employees
- 9
- Website
- ahammune.com/
- Ownership
- Privately Held (backing)
Ahammune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ahammune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ahammune in its N-PORT filings yet. We sweep new filings monthly.